HealthQuill Pharma
Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to continue to advance the end-stage trials of antifungals.
Drugs Medical Pharma

Basilea gets $39 million additional funds from US’s BARDA

HQ Team July 8, 2025: Switzerland’s Basilea Pharmaceutica Ltd. has received an additional $39 million from the US-based Biomedical Advanced Research and Development Authority to.

Read More
KalVista Pharmaceuticals Inc.'s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks in the body, got approval from the US regulator. 
Drugs Health Pharma

KalVista’s oral pill for body swelling disorder gets US regulator’s nod 

HQ Team July 7, 2025: KalVista Pharmaceuticals Inc.’s medicine to treat hereditary angioedema, a rare disease that causes sudden and severe swelling attacks.

Read More
Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over 50 years, has failed to meet its primary goal of being symptom-free after a year of therapy.
Drugs Health Pharma

Novartis’ drug to treat inflammation of arteries fails in end-stage trials

HQ Team July 3, 2025: Novartis AG’s end-stage trial of a drug to treat the inflammation of arteries, which affects people aged over.

Read More
The World Health Organization has unveiled a '3 by 35 initiative,’ urging governments to impose a health tax of about 50% on alcohol, sugary drinks and tobacco that are fuelling a noncommunicable disease (NCD) epidemic globally.
Drugs Health Pharma

Slap 50% tax on alcohol, sugary drinks, tobacco to curb NCDs: WHO

HQ Team July 3, 2025: The World Health Organization has unveiled a ‘3 by 35 initiative,’ urging governments to impose a health tax.

Read More
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More
Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after it failed to meet its main efficacy goal.
Drugs Health Pharma

Organon halts endometriosis drug trial as it fails to meet efficacy goal

HQ Team July 2, 2025: Organon & Co. has discontinued its clinical development programme for an oral medicine to treat endometriosis-related pain after.

Read More
The European Commission has approved Vertex Pharmaceuticals' drug to treat cystic fibrosis in adults and children above six years of age who have certain genetic mutations related to the disease.
Drugs Health Pharma

EC approves Vertex’s once-daily drug combination to treat cystic fibrosis 

HQ Team July 3, 2025:  The European Commission has approved Vertex Pharmaceuticals‘ drug to treat cystic fibrosis in adults and children above six.

Read More
Amgen Inc.’s drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer compared to chemotherapy alone, according to a company statement.
Drugs Health Pharma

Amgen’s trial drug for gastric cancer patients helps them live longer

HQ Team June 30, 2025: Amgen Inc.’s experimental drug to treat advanced gastric cancer, in combination with chemotherapy, showed that people lived longer.

Read More
The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on the table as more information is needed to fully evaluate both, according to the World Health Organization.
Drugs Health Pharma

WHO says more information needed to track SARS-CoV-2 origins

HQ Team June 30, 2025: The two hypothetical origins of the Covid-19 pandemic, namely the animal-to-human transmission and a laboratory leak, remain on.

Read More
Gilead Sciences and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer medicine to treat breast cancer and other solid tumours. 
Drugs Health Pharma

Gilead, Kymera Therapeutics in $750m pact to make new cancer drug

HQ Team June 25, 2025: Gilead Sciences Inc. and Kymera Therapeutics have signed a $750 million license agreement to develop a new cancer.

Read More